DENVER, Oct. 17 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
(Amex: AXK) announced today the signing of an agreement with Promega
Corporation regarding Accelr8's proprietary OptiChem(R) surface chemistry for
use in microarraying slides. The agreement will allow for exploration of new
techniques in microarray research using Accelr8 and Promega technologies.
According to David Howson, Accelr8's president, "This agreement represents
another event for Accelr8 in licensing out our technology components in the
"We're gratified that Promega evaluated the alternatives and chose
OptiChem because of its performance advantages. We are also pleased to be
associated with Promega because of their well-deserved reputation for
excellence," said Howson.
Microarray techniques allow researchers to study massive numbers of
biomolecules in parallel. The technology is based on placing thousands of
different types of biomolecules onto a surface such as a glass microarray
slide. Microarrays have already had a major impact in fields ranging from
cancer research to agriculture, and is rapidly moving from a discovery
research tool to broader applications in medical diagnostics. Accelr8's
OptiChem coatings provide unique performance advantages that help to make
OptiChem-coated slides an enabling component of next generation microarrays.
The ongoing revenues from licensing occur in parallel with Accelr8's
primary business focus in developing the BACcelr8r(TM) rapid bacterial
analysis system. Accelr8 intends the BACcelr8r to become the world's first
diagnostic system to provide complete bacterial antibiotic resistance strain
identification in 8 hours or less. Conventional culturing typically delays
lab results from one to three days, which is inadequate for best management of
rapidly progressing, life-threatening infections in critically ill patients.
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection. In
addition to its microarraying products, Accelr8 is also developing a rapid
clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface
coatings, assay processing, and detection technologies.
SOURCE Accelr8 Technology Corporation